Literature DB >> 27498256

Idarucizumab for Dabigatran Reversal in Emergency Type-A Aortic Dissection.

Reney S Henderson1, Seema Deshpande1, Brittney Williams1, Brad S Taylor2, Kenichi A Tanaka1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27498256     DOI： 10.1053/j.jvca.2016.04.027

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN： 1053-0770            Impact factor:   2.628


× No keyword cloud information.
  4 in total

1.  Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Authors:  Timothy C Hutcherson; Nicole E Cieri-Hutcherson; Rajvi Bhatt
Journal:  P T       Date:  2017-11

2.  Assessment of patients post reversal with idarucizumab.

Authors:  Veronica Raco; Tania Ahuja; David Green
Journal:  J Thromb Thrombolysis       Date:  2018-11       Impact factor: 2.300

3.  Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage.

Authors:  Jonathan Balakumar; Ruben Santiago; Mark Supino
Journal:  Clin Pract Cases Emerg Med       Date:  2017-10-06

4.  Two Dabigatran Fast Reversals in a 4-month Period - a Case Report.

Authors:  Vítor Fagundes; Mari Mesquita
Journal:  Eur J Case Rep Intern Med       Date:  2019-12-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.